- Home
- JZXN vs APVO Comparison
JZXN vs APVO Comparison
Compare JZXN & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JZXN
- APVO
- Stock Information
- Founded
- JZXN 2019
- APVO 2016
- Country
- JZXN China
- APVO United States
- Employees
- JZXN N/A
- APVO N/A
- Industry
- JZXN Retail-Auto Dealers and Gas Stations
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- JZXN Consumer Discretionary
- APVO Health Care
- Exchange
- JZXN Nasdaq
- APVO Nasdaq
- Market Cap
- JZXN 21.8M
- APVO 21.7M
- IPO Year
- JZXN 2021
- APVO N/A
- Fundamental
- Price
- JZXN $0.27
- APVO $1.41
- Analyst Decision
- JZXN
- APVO
- Analyst Count
- JZXN 0
- APVO 0
- Target Price
- JZXN N/A
- APVO N/A
- AVG Volume (30 Days)
- JZXN 10.2M
- APVO 1.5M
- Earning Date
- JZXN 03-05-2026
- APVO 11-10-2025
- Dividend Yield
- JZXN N/A
- APVO N/A
- EPS Growth
- JZXN N/A
- APVO N/A
- EPS
- JZXN N/A
- APVO N/A
- Revenue
- JZXN $97,465.00
- APVO N/A
- Revenue This Year
- JZXN N/A
- APVO N/A
- Revenue Next Year
- JZXN N/A
- APVO N/A
- P/E Ratio
- JZXN N/A
- APVO N/A
- Revenue Growth
- JZXN N/A
- APVO N/A
- 52 Week Low
- JZXN $0.25
- APVO $1.32
- 52 Week High
- JZXN $7.82
- APVO $298.00
- Technical
- Relative Strength Index (RSI)
- JZXN 34.41
- APVO 42.02
- Support Level
- JZXN $0.27
- APVO $1.39
- Resistance Level
- JZXN $0.39
- APVO $1.58
- Average True Range (ATR)
- JZXN 0.05
- APVO 0.07
- MACD
- JZXN 0.02
- APVO 0.00
- Stochastic Oscillator
- JZXN 8.67
- APVO 7.69
About JZXN Jiuzi Holdings Inc.
Jiuzi Holdings Inc operates as a franchise under the brand name Jiuzi. It sells new energy vehicles in third-fourth tier cities in China. The firm also sells plug-in electric vehicles on demand from vehicle buyers. Its operating segments are propretaey product; and resale of sourced Equipment and accessories from third party products. The company generates a majority of its revenue from the propretaey product segment. Geographically, the firm operates in China.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.